What is the recommended weekly DCF (docetaxel, cisplatin, 5‑fluorouracil) dosage regimen for an adult patient with adequate renal (creatinine clearance ≥ 60 mL/min), hepatic (bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN), bone‑marrow function (ANC ≥ 1,500 µL⁻¹, platelets ≥ 100,000 µL⁻¹) and performance status 0‑2?

Weekly DCF Dosage for Advanced Gastric Cancer

For an adult patient with adequate organ function and performance status 0-2, the recommended weekly DCF regimen is: docetaxel 20-35 mg/m² IV, cisplatin 20-30 mg/m² IV, and 5-fluorouracil 350-750 mg/m² as a 24-hour continuous infusion, administered once weekly for 6 consecutive weeks followed by a 2-week break (or for 3 consecutive weeks every 4 weeks). 1, 2

Rationale for Weekly Dosing

The standard every-3-week DCF regimen (docetaxel 75 mg/m², cisplatin 75 mg/m², 5-FU 750 mg/m²/day × 5 days) is highly toxic and poorly tolerated, particularly in patients with performance status 1-2. 3 The FDA-approved gastric cancer dosing is 75 mg/m² docetaxel every 3 weeks 4, but this approach has been modified to improve tolerability.

Specific Weekly Dosing Protocols

Most Validated Regimen (MD Anderson Protocol)

• Docetaxel: 20 mg/m² IV over 1 hour
• Cisplatin: 20 mg/m² IV
• 5-Fluorouracil: 350 mg/m² as 24-hour continuous infusion
• Schedule: Weekly for 6 consecutive weeks, then 2-week break 1

This protocol demonstrated:

• 34% objective response rate
• Median overall survival 8.9 months
• Minimal grade 3-4 hematologic toxicity (granulocytopenia 4%, anemia 9%)
• No febrile neutropenia 1

Alternative Higher-Dose Weekly Protocol

• Docetaxel: 25-35 mg/m² IV
• Cisplatin: 25-30 mg/m² IV
• 5-Fluorouracil: 750 mg/m² as 24-hour continuous infusion
• Schedule: Weekly for 3 consecutive weeks every 4 weeks 2, 5

This approach showed:

• 28% partial response rate in ECOG 1-2 patients
• Median overall survival 12 months
• Grade 3-4 neutropenia 10.9%, thrombocytopenia 7.8% 2

Critical Administration Details

Premedication is mandatory: Oral corticosteroids must be given before each docetaxel dose to prevent hypersensitivity reactions and fluid retention. 4

Infusion sequence matters: Administer docetaxel first, followed by cisplatin, then 5-FU. When using 24-hour cisplatin infusions with 5-FU/leucovorin, severe electrolyte disturbances (hypomagnesemia, hypokalemia) occurred in 41% of patients. Changing to a 3-hour cisplatin infusion after 5-FU/leucovorin eliminated these complications. 6

Do not use PVC equipment for docetaxel administration. Use only a 21-gauge needle to withdraw from vials. 4

Dose Selection Algorithm

1. For ECOG 0-1 patients with normal organ function: Start with higher-dose weekly protocol (docetaxel 25-35 mg/m², cisplatin 25-30 mg/m², 5-FU 750 mg/m²) 2

2. For ECOG 2 patients or those with borderline organ function: Use lower-dose MD Anderson protocol (docetaxel 20 mg/m², cisplatin 20 mg/m², 5-FU 350 mg/m²) 1

3. Dose escalation: If the lower dose is well-tolerated after 2 cycles, consider escalating 5-FU to 1,500-2,000 mg/m² weekly while maintaining docetaxel at 40 mg/m² and cisplatin at 30 mg/m². 5, 6

Toxicity Monitoring and Management

Absolute contraindications: Do not administer if neutrophils <1,500 cells/mm³ or bilirubin >ULN. 4

Weekly monitoring required: CBC before each dose. The weekly schedule allows for dose holds without significantly delaying treatment, unlike every-3-week regimens.

Grade 3-4 toxicities with weekly dosing are substantially lower than standard DCF:

• Neutropenia: 10-27% (vs. >80% with standard DCF)
• Febrile neutropenia: 0-13% (vs. 29% with standard DCF)
• Non-hematologic grade 3-4: <20% 2, 1

Treatment Duration

Administer for a minimum of 2 cycles (16-24 weeks total) to assess response. 2 Patients achieving disease control (complete response, partial response, or stable disease) should continue until progression or unacceptable toxicity. The median number of treatment weeks in clinical studies was 10 weeks. 1

Common Pitfalls to Avoid

1. Do not use the every-3-week FDA-approved dosing (75 mg/m² each drug) in patients with ECOG 1-2, as toxicity will be prohibitive
2. Do not skip corticosteroid premedication - this is non-negotiable for docetaxel administration
3. Do not use 24-hour cisplatin infusions simultaneously with 5-FU - this causes severe electrolyte disturbances
4. Do not treat if creatinine clearance <60 mL/min without dose adjustment, as cisplatin nephrotoxicity risk increases substantially

The weekly DCF approach represents a rational modification that maintains efficacy while dramatically improving tolerability compared to standard every-3-week dosing, making it particularly appropriate for the patient population described with adequate but not exceptional organ function.